51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

Key Points

• St. Louis Financial Planners Asset Management LLC purchased 51,393 Abbott Laboratories shares worth approximately $4.9 million, making Abbott its 10th-largest holding. Institutional investors collectively own 75.18% of the company.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $118.17 price target, although several brokerages recently reduced their targets and Weiss Ratings downgraded the stock to “sell.”
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, up 13% year over year. The company also declared a $0.63 quarterly dividend, equivalent to a 2.3% yield.

St. Louis Financial Planners Asset Management LLC acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 51,393 shares of the healthcare product maker's stock, valued at approximately $4,903,000. Abbott Laboratories comprises approximately 2.5% of St. Louis Financial Planners Asset Management LLC's holdings, making the stock its 10th biggest position.

Other large investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ABT. Weiss Ratings downgraded shares of Abbott Laboratories from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, July 23rd. Raymond James Financial cut their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Benchmark lowered their target price on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a report on Friday, April 17th. Evercore dropped their price target on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Finally, TD Cowen restated a "buy" rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.17.

Abbott Laboratories Trading Up 2.0%

Shares of NYSE:ABT opened at $107.86 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company's 50-day moving average price is $95.06 and its 200 day moving average price is $99.97. The company has a market cap of $186.63 billion, a PE ratio of 34.90, a P/E/G ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source